Psilocybin therapy has moved from the fringes of medicine into some of the best-known research centers in Europe and around the world. Universities in London, Maastricht and Prague, as well as hospitals across North America and Australia, now study how psilocybin, the active compound in magic mushrooms, might help people with depression, anxiety and addiction. This guide explains how psilocybin therapy works, what the research shows so far, where it is available, and who should avoid it.
This article is for general information only. It is not medical advice, and psilocybin therapy should only take place under qualified medical supervision.
What Is Psilocybin Therapy?
Psilocybin therapy, also called psilocybin-assisted psychotherapy, combines one or two carefully controlled doses of psilocybin with structured psychological support. The drug is not taken daily like a typical antidepressant. Instead, the therapy is built around a small number of intensive sessions, with preparation beforehand and follow-up conversations afterward.
In clinical trials, patients usually receive pure, synthetic psilocybin in a capsule rather than mushrooms. As a result, the dose is precise and consistent, which is essential for research. A typical trial dose is around 25 mg of psilocybin, which is roughly comparable to a strong dose of dried mushrooms. For more on how mushroom doses compare, see our magic mushroom dosage guide.
How Psilocybin Therapy Works: The Three Stages
Most psilocybin therapy programs follow the same basic structure, whether they take place in a European university hospital or a licensed center elsewhere.
1. Preparation
First, the patient meets the therapists who will guide the session. Together, they discuss the patient's history, their intentions and what the experience may feel like. Medical and psychiatric screening also takes place at this stage, because psilocybin is not safe for everyone.
2. The Dosing Session
The dosing session usually lasts six to eight hours in a calm, comfortable room. Patients often lie down, wear eyeshades and listen to a selected music playlist. Meanwhile, one or two trained facilitators stay with them throughout. They do not steer the experience, but they offer reassurance if difficult emotions come up. This careful attention to "set and setting," meaning mindset and environment, is a key part of psilocybin therapy.
3. Integration
Finally, in the days and weeks after the session, the patient meets the therapists again to talk through what happened. This integration work helps people turn insights from the session into lasting changes in daily life. Some people also support it with regular practice, as our article on psilocybin and meditation describes. Many researchers believe this stage is just as important as the dose itself.
What Does the Research on Psilocybin Therapy Show?
Research on psilocybin therapy has grown quickly over the past decade, and several of the most influential studies have come from Europe. Smaller studies have also explored other conditions, such as migraine.
Depression
Depression is the most studied area. At Imperial College London, researchers compared psilocybin therapy with escitalopram, a common antidepressant, in a trial published in the New England Journal of Medicine in 2021. On the main measure of depression, the difference between the two treatments was not statistically significant. However, several secondary measures favored psilocybin, and the study helped shape later trials.
In addition, a large international trial led by COMPASS Pathways tested psilocybin in people with treatment-resistant depression at sites across Europe and North America. A single 25 mg dose reduced depression scores more than a very low dose after three weeks. At the same time, side effects such as headache and nausea were common, and the effect was not lasting for everyone. Larger phase 3 trials followed to confirm whether the benefits hold up. For a detailed look at each study, read our guide to psilocybin for depression.
Anxiety and Distress in Serious Illness
Early studies at Johns Hopkins University and New York University found that psilocybin therapy reduced anxiety and depression in people with life-threatening cancer. Many participants still reported benefits months later. These trials were small, but they played a major role in reviving scientific interest in psychedelics. Our article on psilocybin for anxiety covers them in more detail.
Addiction
Researchers have also studied psilocybin therapy for alcohol use disorder and smoking. For example, a trial at New York University found that people with alcohol use disorder who received psilocybin with psychotherapy drank less over the following months than those who received a placebo. Small pilot studies on quitting smoking have shown promising results, too. Even so, larger studies are still needed. Read more in our article on psilocybin for addiction.
What the Research Does Not Show Yet
Overall, the evidence is encouraging but still limited. Many trials are small, and because psilocybin has strong effects, participants often guess whether they received the real drug. That makes placebo-controlled research difficult. Long-term safety and the best way to combine psilocybin with therapy are also still being studied. In short, psilocybin therapy is a promising area of research, not a proven cure. Researchers are also exploring newer areas, such as PTSD, OCD and anorexia, where the evidence is even more limited.
Where Is Psilocybin Therapy Available?
Access to psilocybin therapy depends heavily on where you live. Here is a broad overview, starting with Europe.
- Europe: no psilocybin medicine has EU-wide approval, so most access in Europe is through clinical trials. Universities and hospitals in countries such as the United Kingdom, the Netherlands, Germany, Denmark and the Czech Republic run psilocybin research. Some countries have also started to create limited routes for medical use, so check with your national health authority for the current rules.
- Australia: since July 2023, specially authorized psychiatrists can prescribe psilocybin for treatment-resistant depression.
- United States and Canada: Oregon and Colorado run state-regulated psilocybin programs, while Canada allows access for some patients through special exemptions.
Because laws change often, read our overview of psilocybin legality in Europe and around the world before you make any plans. If you are interested in taking part in a trial, public trial registers and your doctor are the best places to start.
Risks of Psilocybin Therapy and Who Should Avoid It
Even in a supervised setting, psilocybin therapy carries risks. During a session, people may feel intense fear, confusion or sadness. Blood pressure and heart rate can rise, and headaches or nausea are common. These effects usually pass within a day, but difficult experiences can sometimes affect people for longer.
Clinical trials normally exclude people who:
- have a personal or close family history of psychosis or bipolar disorder
- have certain heart conditions or uncontrolled high blood pressure
- take medications that may interact with psilocybin, such as lithium
- are pregnant or breastfeeding
Moreover, many antidepressants can weaken the effects of psilocybin. Never stop or change any medication without talking to your doctor first.
Psilocybin Therapy vs Microdosing
Psilocybin therapy and microdosing are often mentioned together, yet they are very different. Therapy uses a full, strong dose in a few supervised sessions with professional support. Microdosing, on the other hand, involves taking a very small amount regularly, without noticeable psychedelic effects, and it has much weaker scientific support. To learn more, read our guide to microdosing magic mushrooms.
Frequently Asked Questions About Psilocybin Therapy
How many sessions does psilocybin therapy involve?
Most clinical programs use one or two dosing sessions, together with several preparation and integration meetings before and after.
Is psilocybin therapy legal in Europe?
In most European countries, psilocybin therapy is only available through approved clinical trials or limited medical programs. Rules differ from country to country and are changing quickly.
Does psilocybin therapy work for everyone?
No. Some people respond well, while others notice little change or find that benefits fade over time. Researchers are still studying who is most likely to benefit.
Conclusion
Psilocybin therapy is one of the most closely watched areas of mental health research in Europe and around the world. It combines a carefully controlled dose with preparation, support and integration, and early studies on depression, anxiety and addiction are promising. However, the evidence is still developing, access is limited, and the therapy is not suitable for everyone. If you are curious about psilocybin therapy, talk to a qualified doctor and follow trusted research news as the field evolves.
Sources
- Carhart-Harris R, et al. Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine. 2021. doi:10.1056/NEJMoa2032994
- Goodwin GM, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine. 2022. doi:10.1056/NEJMoa2206443
- Bogenschutz MP, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder. JAMA Psychiatry. 2022. doi:10.1001/jamapsychiatry.2022.2096
